GGrantIndex
← Search

Shared Resource Management

$2,713,641P30FY2025CANIH

Northwestern University At Chicago, Evanston IL

Investigators

Linked publications, trials & patents

Trial NCT07639528Trial NCT07594626Trial NCT07594548Trial NCT07290543Trial NCT07261657Trial NCT07178301Trial NCT07169617Trial NCT07050186Trial NCT07042919Trial NCT06959641Trial NCT06813898Trial NCT06723457Trial NCT06630416Trial NCT06571734Trial NCT06499870Trial NCT06410248Trial NCT06327477Trial NCT06247540Trial NCT06244004Trial NCT06242834Trial NCT06184750Trial NCT06164275Trial NCT06137651Trial NCT06062498Trial NCT06060587Trial NCT06022822Trial NCT05879250Trial NCT05852041Trial NCT05802186Trial NCT05744739Trial NCT05733000Trial NCT05620771Trial NCT05576896Trial NCT05545150Trial NCT05453799Trial NCT05419011Trial NCT05411107Trial NCT05236036Trial NCT05202782Trial NCT05093387Trial NCT04931017Trial NCT04910425Trial NCT04795869Trial NCT04767984Trial NCT04753216Trial NCT04576104Trial NCT04550481Trial NCT04250051Trial NCT04227028Trial NCT04200443Trial NCT04049227Trial NCT04047706Trial NCT04033432Trial NCT04009044Trial NCT03854474Trial NCT03812562Trial NCT03742258Trial NCT03723915Trial NCT03704714Trial NCT03513484Trial NCT03317405Trial NCT03278925Trial NCT03226249Trial NCT03213041Trial NCT03146650Trial NCT03077828Trial NCT03070002Trial NCT03061188Trial NCT03048500Trial NCT03044730Trial NCT03036930Trial NCT03020017Trial NCT02993159Trial NCT02968810Trial NCT02965703Trial NCT02901899Trial NCT02892734Trial NCT02871323Trial NCT02861040Trial NCT02847559Trial NCT02837029Trial NCT02819804Trial NCT02808143Trial NCT02805868Trial NCT02794883Trial NCT02774681Trial NCT02743364Trial NCT02720484Trial NCT02694809Trial NCT02536794Trial NCT02530619Trial NCT02530502Trial NCT02530125Trial NCT02481310Trial NCT02365480Trial NCT02357810Trial NCT02314156Trial NCT02242097Trial NCT02237183Trial NCT02232516

Abstract

PROJECT SUMMARY / ABSTRACT The Robert H. Lurie Comprehensive Cancer Center (LCC) provides strategic and scientific oversight and allocates funds to support 14 Shared Resources (SR), 13 of which are established and one of which is developing. The mission of SR Management (SRM) is to support the SRs so that they can provide exceptional service to LCC members to advance cancer research. LCC support to SRs facilitates and enables a broad spectrum of basic, preclinical, clinical, and population sciences research, representing all programs of the center. SRM is overseen by the Associate Director (AD) for Shared Facilities, who also chairs the Shared Resources Oversight Committee (SROC). The AD for SRs works closely with the ADs of Basic, Translational, Clinical and Population Sciences to maximize the impact of the SRs on science and clinical translation. He also collaborates with the AD for CRTEC to plan seminars, webinars, and other informational events, to ensure that LCC members are fully informed of the capabilities of all SRs. During the current funding period - in addition to securing 11 NIH S10 grants - LCC invested $6.2M, leveraged by institutional support of $20.4M to support SR operations, upgrade equipment, create a new developing SR, and optimally align SR capabilities with the needs of our members, according to the LCC Strategic Plan. During this funding cycle, the LCC SRs have had a profound enabling impact on academic productivity, as reflected by its support of 427 high impact (IF>10) publications and 888 NIH grants. NUCORE – the transaction processing system that permits shared resources to accept and track orders and to bill for their services – was originally developed by the LCC and has been adopted subsequently throughout Northwestern University (NU). This program continues to be upgraded, with updates and new features released bi-weekly, and is currently used by other academic cancer programs in the country. During the next funding period, it is expected that the Immune Assessment Core (IAC), a new developing shared resource of high LCC priority, will be able to transition to an established core. This facility has emerged in response to member input, through LCC strategic planning, and as a result of ongoing expansion of the cancer immunology and immunotherapy capabilities of the LCC. The LCC will also continue the use of artificial intelligence (AI), a strong component of NU and LCC expertise, to further optimize and expand its Core Navigation system, developed during this grant period, into an AI powered chat bot.

View original record on NIH RePORTER →